Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Brain Neoplasms 3Multiple Myeloma 2Lymphoma 2Prostatic Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Localized, Operable Non-small Cell Lung Cancer 1Liver Neoplasms 1Liver Diseases 1Fibrosis 1Fatigue 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Cancer Related Cognitive Difficulties 1Breast Neoplasms 1

Interventions

Rituximab 88Cyclophosphamide 81Prednisone 48Doxorubicin 44Lenalidomide 37Vincristine 35polatuzumab vedotin 29Magnetic Resonance Spectroscopy 29Gemcitabine 27Etoposide 26Specimen Handling 25fludarabine 23Biopsy 21Oxaliplatin 20CT-P10 20glofitamab 17tafasitamab 15obinutuzumab 15ibrutinib 14zanubrutinib 13fludarabine phosphate 13pembrolizumab 12axicabtagene ciloleucel 12Immunotherapy, Adoptive 12Ifosfamide 12venetoclax 11deltacortene 11prednylidene 10Prednisolone 10Leukapheresis 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Neuropsychological Tests × 1 year × Clear all
NCT04319237 2026-03-02

Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

H. Lee Moffitt Cancer Center and Research Institute

Completed
60 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡